DLBCL	Diffuse large B-cell lymphoma
LBCL	large B-cell lymphoma
r/r	relapsed or refractory
CAR	chimeric antigen receptor
axi-cel	axicabtagene ciloleucel
tisa-cel	tisagenlecleucel
liso-cel	lisocabtagene maraleucel
ORR	overall response rate
CR	complete response
PR	partial response
OS	overall survival
PFS	progression-free survival
EFS	event-free survival
DOR	duration of response
SOC	standard of care
GES	gene expression signatures
tHGBCL	Transformed High-Grade B-Cell Lymphoma
FL	Follicular lymphoma
IQR	Interquartile Range
NOS	Not Otherwise Specified
HGBCL	High-Grade B-Cell Lymphoma
TME	Tumor Microenvironment
DHL	Double-Hit Lymphoma
Flu/Cy	Fludarabine + Cyclophosphamide
LN	lymphoid-enriched
FMAC	fibroblast/macrophage-enriched
TEX	T-cell-exhausted
DFS	Disease-Free Survival
PD	Progressive Disease
CI	Confidence Interval
CRS	Cytokine Release Syndrome
ICANS	Immune Effector Cell-Associated Neurotoxicity Syndrome
B-ALL	B-cell Acute Lymphoblastic Leukemia